×

Neville Registrars is delighted to welcome Warpaint London Plc as the newest addtion to its list of client companies.

Warpaint London sells colour cosmetics in the UK and overseas, pricipally under the W7 brand.

Further information can be found on the Company's website: https://www.w7cosmetics.co.uk/

Close

×

Neville Registrars is delighted to welcome Gunsynd Plc as the newest addtion to its list of client companies.

The Company’s Investing Policy is to invest in and/or acquire companies and/or projects within the natural resources sector.

Further information can be found on the Company's website: http://www.gunsynd.com/

Close

×

RNS Number : 2381Q

Nanoco Group PLC

28 November 2016

 

For immediate release

28 November 2016

 

 

 

NANOCO GROUP PLC

("Nanoco" or the "Company") 

 

Acquires Quantum Dot Patents from Kodak

 

Nanoco Group plc (LSE: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other nanomaterials, announces that it has acquired a group of patents from the Eastman Kodak Company ("Kodak") in connection with the use of quantum dots in electroluminescent displays, a future display technology.

This patent acquisition, which is in line with Nanoco's strategy of building its patent estate organically and by acquisition, reinforces the Company's intellectual property position in quantum dot electroluminescent displays (QLED), a future technology in which quantum dots can be used to replace the current materials in organic light emitting diode (OLED) displays.

Nanoco is building a patent position in anticipation of many future applications of quantum dots including QLED, a technology that Nanoco has researched for almost 10 years.  Display sales in the medium term are expected to remain dominated by liquid crystal display ("LCD") technology, which is Nanoco's current commercial focus.

The commercial terms of the patent acquisition are undisclosed.

Michael Edelman, Nanoco's Chief Executive Officer, said: "This patent purchase from Kodak broadens our intellectual property estate and commercial position in future display technologies.  The vast majority of current displays are based on LCD technology and we expect LCDs to dominate display sales in the near and medium term. In the longer term, QLED displays could challenge current OLED displays and we aim to have a strong competitive position in this space in preparation for any market change. Our current focus remains driving near term revenue from the supply to the LCD industry of the Company's cadmium-free quantum dots manufactured and marketed by Nanoco and our licensees, Dow, Merck and Wah Hong."

 

This announcement contains inside information.

 

For further information, please contact:

 

Nanoco	Tel: +44 (0) 161 603 7900
Michael Edelman, Chief Executive Officer
David Blain, Chief Financial Officer
Caroline Watson, Investor Relations Manager	Tel: + 44 (0) 7799 897357
cwatson@nanocotechnologies.com
Peel Hunt	Tel: +44 (0) 20 7418 8900
Adrian Trimmings
George Sellar
Buchanan	Tel: +44 (0) 20 7466 5000
Mark Court / Sophie Cowles / Stephanie Watson

 

 

Notes for editors:

 

About Nanoco Group plc

Nanoco is a world leader in the development and production of cadmium-free quantum dots and other nanomaterials for use in multiple applications including LCD displays, lighting, solar cells and bio-imaging. In the display market, Nanoco has a non-exclusive manufacturing and marketing licensing agreements with The Dow Chemical Company, Merck KGaA and Taiwan's Wah Hong Industrial Corporation. Nanoco also has a strategy of direct sales in display and in its other target markets, including lighting.

 

Nanoco was founded in 2001 and is headquartered in Manchester, UK. It has production facilities in Runcorn, UK, and a US subsidiary, Nanoco Inc, based in Concord, MA. Nanoco also has business development executives in Japan, Korea and Taiwan. Its technology is protected worldwide by a large and growing patent estate.

 

Nanoco is listed on the main market of the London Stock Exchange and trades under the ticker symbol NANO. For further information please visit: www.nanocogroup.com.

 

 

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

ACQLDLLLQFFBFBB

Close

×

RNS Number : 2009Q

Trakm8 Holdings PLC

28 November 2016

 

TRAKM8 HOLDINGS PLC

 

("Trakm8" or the "Group")

 

Smart Drivers Club Awards Trakm8 Telematics Contract

 

 

Trakm8, the AIM-listed telematics and data insight provider to the global market place, is pleased to announce it has been awarded a contract by Smart Driver Club ("SDC"), the innovative UK vehicle services company, to supply devices and data services for the launch of its Smartbubble service solution.

 

Trakm8 will provide the latest generation T10 Micro devices and the data set created over many years of extensive engineering development as part of the Trakm8connectedcare solution. This service comprises of client logistics and predictive diagnostic service requirements such as crash detection and theft tracking. SDC expects to have a requirement for a substantial number of devices in the first 18 months of the contract with a launch order of 6,000 devices to be delivered in Trakm8's current financial year.

 

John Watkins, Executive Chairman of Trakm8 commented: 

"We are delighted to have added SDC as a customer for Trakm8's automotive telematics solutions. SDC has an experienced telematics insurance management team who have worked with numerous hardware and data suppliers in the past.

 

"To be chosen as SDC's new partner for its launch is not only a major vindication of our data capabilities but also that our significant investment in research and development is directly leading to sales.

 

"This contract provides additional visibility for our expectations for the current financial year and beyond."

 

 

-ends-

 

For further information please contact:

 

Trakm8 Holdings plc	+44 (0) 174 785 8444
John Watkins, Executive Chairman
James Hedges, Finance Director
finnCap (Nomad and broker)	+44 (0) 20 7220 0500
Ed Frisby / Simon Hicks – corporate finance
Joanna Scott – corporate broking
MHP Communications	+44 (0) 20 3128 8100
Reg Hoare
Jade Neal

 

 

About Trakm8

Trakm8 is a UK based Big Data company utilising telematics as its primary enabler. Through IP owned technology, over three billion miles worth of data is collected annually through its fleet management solutions to create and fine tune algorithms used to score driver behaviour, monitor vehicle health and continuously improve the security and operational efficiencies of customers' vehicles.

With its headquarters in Dorset and a manufacturing facility in the West Midlands, the Group supplies a number of well-known customers in the fleet management and insurance sectors across the UK and further afield including customers such as the AA, Saint Gobain, EON, Direct Line Group and Young Marmalade.

The Group's portfolio offers complete telematics solutions including dashboard cameras that enable customers to record driving incidents and mitigate the risk from "crash to cash" accidents. This is complemented through a comprehensive hardware range, which includes a self-install unit that is one of the smallest available on the global market.

The Group has recently acquired both Route Monkey and Roadsense Technologies Ltd. Route Monkey has enhanced Trakm8's logistics solution offering route scheduling and optimisation, including routing for electric vehicles. Roadsense has been acquired to strengthen the Group's presence in the SME fleet management market.

Trakm8 has been listed on the AIM market of the London Stock Exchange since 2005.

www.trakm8.com / @Trakm8

 

About Smart Driver Club

Smartdriverclub is a completely unique membership service for motorists with vehicles manufactured since 2008.  The business was created by Penny Searles, harnessing her 8 years' experience in the motor insurance sector. Smartdriverclub is using technology from global providers of wireless products, services and end-to-end solutions some with 30 years' experience in the field. Smartdriverclub valuations are supported by cap hpi, the mechanic support is provided by CallAssist. Smart Driver Club Limited is Registered in England and Wales with company number 09706245. Registered office address: Timsons Business Centre, Bath Road, Kettering, Northamptonshire, England NN16 8NQ.

 

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRAUVRURNBAAUAA

Close

×

RNS Number : 7636P

Gresham House PLC

22 November 2016

 

22 November 2016

Gresham House plc ("Gresham House" or the "Company")

(AIM: GHE)

GRESHAM HOUSE REBRANDS FORESTRY DIVISION AND COMPLETION OF FIRST ACQUISITON BY GRESHAM HOUSE FORESTRY FUND

Gresham House plc, the specialist asset manager focused on alternative asset management strategies ("the Company") is pleased to announce the re-branding of its dedicated forestry asset management business, Aitchesse Ltd, as Gresham House Forestry ("GHF").  

GHF manages £238 million of assets on behalf of endowments, institutions, family offices and private investors and was acquired by the Company in November 2015.  The re-branding follows the successful £15 million first close of the Gresham House Forestry Fund LP ("The Fund"), which is targeting a total fundraising of £50 million at final close in 2017. 

In addition, the Company is pleased to confirm that the Fund has now completed its first investment through the purchase of five forests in the west of Scotland for £12 million referred to in the recent announcement on 31 October 2016.  The Fund is targeting annual returns of 10% including a yield of between 2% and 4%. 

Gresham House now has three divisions formed within its specialist asset management platform managing c.£375 million of third party assets:

‒     Strategic Public Equity managing a quoted investment company Gresham House Strategic plc ("GHS") and a Limited Partnership ("SPE Fund LP");

 

‒     Private Equity managing listed investment company LMS Capital plc; and

 

‒     Real Assets, formed through the establishment of its Forestry business managing third party assets through segregated mandates, managed accounts and the Gresham House Forestry Fund LP.

Tony Dalwood, Chief Executive of Gresham House plc said

"We are nearly two years into the development of Gresham House as a 'go-to' provider of alternative asset management strategies. We enter 2017 with a clear plan to continue to grow organically and with a number of corporate opportunities being appraised which would enable us to continue to scale our specialist asset management platform and accelerate the path to profitability, working closely alongside strategic partners and shareholders."

 

Enquiries:

Gresham House plc
Anthony Dalwood	+44 (0) 20 3837 6270
Montfort Communications, PR Adviser
Gay Collins	+44 (0) 203 770 7906
Rory King	greshamhouse@montfort.london
Liberum
Neil Elliot/Jill Li	+44 (0) 20 3100 2000

 

www.greshamhouse.com

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRAKMMZMGMKGVZZ

Close

×

RNS Number : 7650P

Midatech Pharma PLC

22 November 2016

 

 

 

 

22 November 2016

 

Midatech Pharma PLC

("Midatech" or the "Company")

 

Midatech provides update on agreement with Emergex Vaccines

 

Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology, today announces that following the licence granted to Emergex Vaccines Limited (announced 4 January 2016) Midatech has received an upfront technology access fee and option payment of £450,000 under the terms of the contract.  

 

This exclusive licensing agreement covers the use of Midatech's proprietary gold nanoparticle platform in the development of vaccines for influenza, meningitis, bacterial pneumonia, Ebola virus, Marburg virus and viruses within the Arbovirus class such Zika and Dengue. This is the first deployment of Midatech's gold nanoparticles as a conventional vaccine for infectious disease.

 

Under the agreement, the licence, together with the Service and Manufacturing Agreement for both the synthesis and development manufacturing of cGMP material for clinical trials, was novated from Emergex Vaccines Limited to a related entity Emergex Vaccines Holding Limited ("Emergex"), a private UK biotechnology company focused on developing synthetic T-cell vaccines against new and emerging infectious diseases.

 

Midatech will continue to be entitled to receive certain milestone and royalty payments, as well as service fees, as part of the arrangement.

 

Commenting on the announcement, Dr. Jim Phillips, CEO of Midatech Pharma, said: "I am pleased to see progress being made in the adaptation of our gold nanoparticle technology for use in vaccines for infectious disease, which perfectly complements our type 1 diabetes collaboration in antigen specific immunotherapy, and our early-stage internal programs which address auto-immune disease and immuno-oncology."

 

David Jackson of Emergex added: "The expansion of the Midatech licence with Emergex is important for the development of cross-reactive or universal vaccines against infectious agents sharing common genetic characteristics such as flavi viruses within the Arbovirus group. There were 380 million new cases of Dengue last year and Zika is becoming a global health problem. The licence with Midatech now allows Emergex to develop vaccines that are not restricted to a single flavi virus but potentially act as a universal vaccine against Zika, Dengue and other flavi viruses. This is a continuation of our universal influenza vaccine program which also targets genetic components common to all influenza viruses. Our synthetic T cell mediated vaccines should also be able to safely immunize pregnant women and provide co-immunisation of the foetus which may be required for prevention of the congenital Zika syndrome."

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR)

 

– Ends –

 

 

For more information, please contact:

 

Midatech Pharma PLC

Jim Phillips, CEO

Tel: +44 (0)1235 841575

www.midatechpharma.com

 

Panmure Gordon (UK) Limited (Nominated Adviser and Broker)

Corporate Finance

Freddy Crossley / Duncan Monteith

Broking

Tom Salvesen

Tel: +44 (0)20 7886 2500

 

Consilium Strategic Communications (Financial PR)

Mary Jane Elliott / Ivar Milligan / Hendrik Thys

Tel: +44 (0)20 3709 5700

Email: midatech@consilium-comms.com

 

Westwicke Partners (US Investor Relations)

Chris Brinzey

Tel: +1 339 970 2843

Email: chris.brinzey@westwicke.com

 

Emergex Vaccines Holding Limited

Storme Moore-Thornicroft

Tel: +44 (0) 7766 705 871

 

Notes for Editors

 

About Midatech Pharma PLC

 

Midatech is an international specialty pharmaceutical company focused on oncology and other therapeutic areas with a US commercial operation marketing four cancer care supportive products, and co-promoting two others. Midatech's strategy is to internally develop oncology products and collaborate with partners in other therapy areas, and to drive growth both organically and through strategic acquisitions. The Company's R&D activities are supported by two breakthrough drug delivery technologies: Q-Sphera for sustained release and our proprietary gold nanoparticles. The Group, listed on AIM: MTPH and Nasdaq: MTP, employs c.110 staff in four countries. For further company information see: www.midatechpharma.com

 

About our gold nanoparticle (GNP) technology

The patented gold nanoparticle (GNP) technology has been developed to improve key parameters when bound to existing and new drugs. GNPs comprise of a core of gold metal atoms to which an organic layer of carbohydrates or glycans (e.g. glucose, galactose or lactose) are attached via gold-sulphur bonds. Linkers for therapeutic agents (e.g. small molecules and chemotherapeutics) and peptides are attached to the gold core during the formation process. This process involves intricate and scalable synthesis that produces multi-component particles that may deliver multiple drug molecules to the targeted site. The GNP platform has potential uses in oncology, immunology/ auto-immunology and neurology, amongst other uses.

 

About Emergex Vaccines Holding Limited

 

Emergex was formed with the vision of tackling the global threats of infectious disease by utilising a novel T-cell synthetic vaccine technology. These vaccines are quick to develop, inexpensive to make, do not require cold chain and can be made quickly in quantity, thus overcoming many of the disadvantages of traditional vaccine technologies. Many developed nations have a national defence strategy of stockpiling large amounts of certain vaccines for use in the event of pandemics or terrorist activity.  The current practice is very expensive and the Emergex technology could greatly increase the quantities of vaccine available and substantially decrease the costs over time.

Emergex's lead products include a triple target vaccine against Zika, Dengue and Chikungunya, and vaccines against Ebola and a pandemic flu.

 

Forward-Looking Statement

Certain statements in this press release may constitute "forward-looking statements" within the meaning of legislation in the United Kingdom and/or United States. Such forward-looking statements include, but are not limited to, statements regarding the ability of Midatech to successfully test, manufacture, produce or commercialise products for conditions using the nanoparticle and sustained release drug delivery platforms, and the ability for products in development to achieve positive clinical results, and the ability to meet or achieve timelines associated with pre-clinical studies, clinical trials or regulatory submissions. Any forward-looking statements are based on currently available competitive, financial and economic data together with management's views and assumptions regarding future events and business performance as of the time the statements are made and are subject to risks and uncertainties. We wish to caution you that there are some known and unknown factors that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements.

 

Reference should be made to those documents that Midatech shall file from time to time or announcements that may be made by Midatech in accordance with the London Stock Exchange AIM Rules for Companies ("AIM Rules"), the Disclosure and Transparency Rules ("DTRs") and the rules and regulations promulgated by the US Securities and Exchange Commission, which contains and identifies other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Midatech are expressly qualified in their entirety by the cautionary statements above. Except as may be required under the AIM Rules or the DTRs or by relevant law in the United Kingdom or the United States, Midatech does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or otherwise arising.

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

MSCPGGBCGUPQPGG

Close

×

Neville Registrars is delighted to welcome Pressure Technologies plc as the newest addtion to its list of client companies.

Pressure Technologies listed on AIM in June 2007 with the goal of building a highly profitable group of companies, specialising in technology for the containment and control of liquids and gases in pressure systems.

Further information can be found on the Company's website: http://www.pressuretechnologies.com/home

Close

×

Neville Registrars is delighted to welcome Intelicrypt Tactical Solutions Limited as the newest addtion to its list of client companies.

 

Close

×

RNS Number : 5178P

The Mission Marketing Group PLC

18 November 2016

 

 

 

 

 

17 industry awards for Mission Agencies

 

 

The Mission Marketing Group plc ('the missiontm', "the Company", AIM: TMMG), the marketing communications and advertising group, is delighted to announce that two Agencies of the missiontm, bigdog and Chapter, collectively scooped a record 17 wins at The Drum Cream Awards held on 16 November.

 

bigdog secured the coveted Grand Prix award for its 'Party Animals' campaign on behalf of World Meat Free Day, marking the second consecutive year the Agency has received the accolade. In addition, bigdog and Chapter each won a further eight awards, making it the largest haul to date at Cream for both Agencies.

 

David Morgan, Chairman of the missiontm, commented: "These Awards are the latest in a long history of success for missiontm Agencies and again recognise that we have some of the very best talent in creative advertising and design across the Midlands, East, South West and Wales. I'm extremely proud of what we continue to achieve."

 

Enquiries   David Morgan, Chairman   Peter Fitzwilliam, Finance Director   The Mission Marketing Group plc	020 7462 1415
Geoff Nash/James Thompson (Corporate Finance) Stephen Norcross (Corporate Broking)
finnCap Limited	020 7220 0500

 

 

the missiontm is a network of entrepreneurial marketing communications Agencies employing over 950 people in the UK, Asia and San Francisco. The Group comprises a complementary mix of integrated generalists, specialists in specific marketing/communications activities and specialists in particular market sectors, all providing award-winning solutions to national and international Clients.  www.themission.co.uk

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRAFFDFAWFMSELF

Close

×

RNS Number : 3941P

Genedrive PLC

17 November 2016

 

RNS  

 

For release: 17 November 2016

 

genedrive plc ("genedrive" or the "Company")

 

genedrive plc Announces CE-IVD Certification for Genedrive® Human Genotyping Test

 

Approval of IL28B Test Further Validates Genedrive® Platform for Rapid Point of Care Human Genotyping

 

genedrive plc (LSE: GDR), the near patient molecular diagnostics company, today announces the CE-IVD certification of its rapid Genedrive® IL28B SNP human genotyping test. The test is performed in 50 minutes from a buccal cheek swab using the Genedrive® hand-held real-time PCR instrument. The CE-IVD certification further validates Genedrive® as a technology platform for pharmacogenomics.

 

David Budd, CEO of genedrive plc, said: "We are now looking to partner with Pharma and Contract Research Organisations to support the development of SNP assays for clinical trials and clinical applications. Through our development of the IL28B test, we have defined a rapid pathway for the generation of a quick, accurate, and effective human genotyping tests that can be deployed at the point of need. While the treatment of HCV has evolved since we started the EU sponsored IL28B programme, the outcome clearly shows how our innovative technology can be put into practice in pharmacogenomics applications."

 

The Genedrive® platform and its polymorphism genotyping capabilities make it an appropriate solution for on the spot stratification, negating the need for costly and time consuming patient recall whilst central laboratory tests are processed.  Similarly, the low instrument cost, simplicity of operation, and connectivity options make it an ideal platform for deployment to large numbers of coordinated trial sites.

 

The data supporting the CE-IVD application showed that the Genedrive® human genotyping IL28B SNP test was 100% accurate in detecting inherited genetic polymorphisms in HCV patients when compared to the current 'gold-standard' laboratory test (Roche TaqMan® PCR). Genedrive® produces results in 50 minutes compared to the standard approach which uses a blood sample and which can have a service lab return time of 2 -3 weeks for results.

 

The company announced in August that that the Genedrive® IL28B human genotyping test will be used in the STOP-HCV-1 clinical trial being run by STOP-HCV, a consortium designed to use stratified medicine to optimise the treatment of patients with Hepatitis C Virus infection. The trial is designed to assess the effectiveness of different treatment durations with Direct Acting Antiviral treatments on HCV Genotype 1 patients (http://www.stop-hcv.ox.ac.uk/stop-hcv-1-trial).

 

–  Ends  –

 

For further details please contact:

genedrive plc

David Budd: CEO                                                                                                              +44 (0)161 989 0245

 

Peel Hunt LLP

James Steel                                                                                                                       +44 (0)207 418 8900

Oliver Jackson

 

Consilium Strategic Communications

Chris Gardner                                                                                                                    +44 (0)203 709 5700

Matthew Neal

Laura Thornton

genedrive@consilium-comms.com 

 

 

Notes to Editors

 

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® platform and MTB/RIF test have been launched in India and a Genedrive® HCV test has been successfully assessed by the Institut Pasteur, Paris.

 

genedrive plc was formerly Epistem plc and continues to provide contract research services to drug development companies under the Epistem brand name.

 

Further details can be found at: www.genedriveplc.com and www.genedrive.com 

 

 

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRAEAXFKFLXKFFF

Close